Skip to main content
Print Save

Generic Xerava Availability

Last updated on Jan 11, 2023.

Xerava is a brand name of eravacycline, approved by the FDA in the following formulation(s):

XERAVA (eravacycline dihydrochloride - powder;intravenous)

  • Manufacturer: TETRAPHASE PHARMS
    Approval date: August 27, 2018
    Strength(s): EQ 50MG BASE/VIAL [RLD]
  • Manufacturer: TETRAPHASE PHARMS
    Approval date: June 3, 2020
    Strength(s): EQ 100MG BASE/VIAL [RLD]

Has a generic version of Xerava been approved?

No. There is currently no therapeutically equivalent version of Xerava available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xerava. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,961,190

    Patent expiration dates:

    • October 19, 2037
      ✓ 
      Drug substance
  • C7-fluoro substituted tetracycline compounds
    Patent 8,796,245
    Issued: August 5, 2014
    Assignee(s): TetraPhase Pharmaceuticals, Inc.

    The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

    Patent expiration dates:

    • August 7, 2029
      ✓ 
      Patent use: TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER
  • C7-fluoro substituted tetracycline compounds
    Patent 8,906,887
    Issued: December 9, 2014
    Assignee(s): Tetraphase Pharmaceuticals, Inc.

    The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

    Patent expiration dates:

    • December 28, 2030
      ✓ 
      Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • August 27, 2023 - NEW CHEMICAL ENTITY
    • August 27, 2028 - GENERATING ANTIBIOTIC INCENTIVES NOW

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer